These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24471477)

  • 1. Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects.
    Matsuguma K; Matsuki S; Eunhee C; Watanabe A; Tanaka A; Sakamoto K; Takeshita H; Hitaka A; Shigetome K; Kimura M; Miyamoto A; Irie S; Kaneko D; Ohnishi A
    Drug Dev Ind Pharm; 2015 Mar; 41(3):470-5. PubMed ID: 24471477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men.
    Matsuguma K; Matsuki S; Sakamoto K; Shiramoto M; Nakagawa M; Kimura M; Irie S; Kaneko D; Ohnishi A
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):99-104. PubMed ID: 27128214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
    Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
    BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.
    Lubenau H; Sveikata A; Gumbrevicius G; Macijauskiene J; Fokas V; Kazlauskas S; Janulionis V
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):275-82. PubMed ID: 19356394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
    Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg
    Roth K; Lehnick D; Wessels H; Höfler J; Gastl B; Jankowsky R
    Pharmacol Res Perspect; 2019 Oct; 7(5):e00503. PubMed ID: 31417680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.
    Sveikata A; Gumbrevičius G; Seštakauskas K; Kregždytė R; Janulionis V; Fokas V
    Medicina (Kaunas); 2014; 50(3):144-9. PubMed ID: 25323541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen
    Yao HM; Ottery FD; Borema T; Harris S; Levy J; May TB; Moosavi S; Zhang J; Summers M
    BioDrugs; 2019 Apr; 33(2):207-220. PubMed ID: 30900158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
    Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
    Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
    Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
    BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
    Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
    Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence of a biosimilar enoxaparin sodium to Clexane
    Martínez González J; Monreal M; Ayani Almagia I; Llaudó Garín J; Ochoa Díaz de Monasterioguren L; Gutierro Adúriz I
    Drug Des Devel Ther; 2018; 12():575-582. PubMed ID: 29593380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.
    Choi C; Yoo BW; Kim CO; Hong T; Jin BH; Seo KS; Jang JY; Park MS
    Drug Des Devel Ther; 2018; 12():2381-2387. PubMed ID: 30122896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilarity Assessment of 2 Filgrastim Therapeutics in Healthy Volunteers.
    Khandoozi SR; Shahbazi M; Amini H
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):346-352. PubMed ID: 32820861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
    Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
    Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
    Singh I; Attrey A; Garg A; Patel R; Jose V
    Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
    Singh I; Patel A; Patel R; Jose V
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.
    Ahn LY; Shin KH; Lim KS; Kim TE; Jeon H; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Drug Investig; 2013 Nov; 33(11):817-24. PubMed ID: 24078278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
    Hanes V; Chow V; Pan Z; Markus R
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
    Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.